BioTalk Unzipped

In this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe welcome Dr. Nathan Teuscher, a seasoned expert in clinical pharmacology and pharmacometrics. The conversation explores Nathan's career journey, the innovative charity Light the World, and the transformative role of AI in drug development. They discuss the challenges and opportunities presented by AI, particularly in automating data analysis and rethinking traditional reporting methods in the pharmaceutical industry. The episode emphasizes the potential for small companies to leverage cloud-based tools and APIs to enhance efficiency and drive innovation in drug development. In this conversation, the speakers explore the intersection of data analysis, AI tools, and advancements in gene editing with organ transplants. Chapters 00:00 Episode Preview 00:55 Introduction to BioTalk Unzipped 02:06 Charity Spotlight: Light of the World 04:51 Nathan Teuscher's Career Journey 07:34 Differentiating AI Types in Life Science 12:41 Challenges with Large Language Models 15:39 Rethinking Reporting in Pharma 17:56 The Future of AI and Analytics in Pharma? 18:52 Leveraging APIs (Application Programming Interfaces) for Small Companies 23:05 Leveraging Data, AI, and APIs in 3 Dimensions 26:22 NEW NEWS! - Gene Editing Breakthroughs in Medicine How to reach us: Light the World Charity - Church of Jesus Christ Latter Day Saints https://www.churchofjesuschrist.org/comeuntochrist/light-the-world [https://www.churchofjesuschrist.org/comeuntochrist/light-the-world]  Nathan Teuscher https://www.linkedin.com/in/nathanteuscher/ [https://www.linkedin.com/in/nathanteuscher/]  Aplos Analytics - https://aplosanalytics.com/ [https://aplosanalytics.com/]  Nathan Teuscher’s Podcast: Clinical Pharmacology Podcast https://teuschersolutions.com/ [https://teuschersolutions.com/]  Collaboration with BioTalk Unzipped (Ep. 40) https://podcasts.apple.com/us/podcast/collaboration-with-biotalk-unzipped-ep-40/id1695617234?i=1000682122951 [https://podcasts.apple.com/us/podcast/collaboration-with-biotalk-unzipped-ep-40/id1695617234?i=1000682122951]  Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ [https://www.linkedin.com/in/chadbriscoe/]  Celerion - https://www.celerion.com/ [https://www.celerion.com/]   Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ [https://www.linkedin.com/in/gregoryaustin1/]  ECI - https://eci-rx.com [https://eci-rx.com] /  Sound Bites "We don't need to write reports anymore." Takeaways * Nathan Teuscher has over 20 years of experience in clinical pharmacology and pharmacometrics. * Light the World charity offers unique giving machines for donations. * AI can automate repetitive tasks in drug development, freeing up human capital for innovation. * There are two types of AI: large language models and automated data analysis. * Large language models can be unreliable in scientific contexts. * Pharmaceutical companies spend significant resources on report writing, which may not add value. * Small companies can leverage APIs to access standardized calculations and data analysis. * The pharmaceutical industry is often insular, limiting the potential of AI. * AI could potentially eliminate the need for extensive written reports in drug development. * Collaboration and data sharing are crucial for advancing AI in the pharmaceutical industry. Leveraging data effectively requires combining various data sets and tools. * The evolution of AI tools is crucial for navigating new technologies. * Gene editing represents a significant breakthrough in organ transplantation. New News Story:  * A woman in the US is the third person to receive a gene-edited pig kidney * https://www.technologyreview.com/2024/12/17/1108905/a-woman-in-the-us-is-the-third-person-to-receive-a-gene-edited-pig-kidney/ [https://www.technologyreview.com/2024/12/17/1108905/a-woman-in-the-us-is-the-third-person-to-receive-a-gene-edited-pig-kidney/] Image Credits * Pig Kidney, https://ny1.com/nyc/all-boroughs/news/2023/08/16/pig-kidney-works-in-a-donated-body-for-over-a-month--a-step-toward-animal-human-transplants [https://ny1.com/nyc/all-boroughs/news/2023/08/16/pig-kidney-works-in-a-donated-body-for-over-a-month--a-step-toward-animal-human-transplants]  Keywords BioTalk, pharmacology, AI in pharma, drug development, pharmacometrics, software development, clinical research, Light the World, charity, data analysis, AI tools, gene editing, kidney transplant, pharmaceuticals, virtual trials, healthcare innovation, drug development, patient engagement, medical technology, drug dosage, oncology, FDA approval, cell therapy, immunocompromised, collaboration, success, clinical pharmacology, podcast, healthcare

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.  Chapters 00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360 03:45 Samaritan's Purse Charity and Community Impact 05:16 Most impactful talk at AAPS? 11:50 Comparative Analysis of FDA and EU Regulations 17:37 The Drive Behind Bioanalytical Work 22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis Takeaways * The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials. * Community support through charities like Samaritan's Purse is crucial during crises. * The importance of collaboration in advancing drug development and bioanalytical methods. * Innovations in RNA editing present new bioanalytical challenges. * The drive to help patients is a key motivator for professionals in the field. * Sound Bites * "I worked on that drug and there's a clear benefit." * "It's getting that new therapy to a patient." * "This is going to change and potentially delay biomarkers." * New News Story:  * Wave sees RNA editing validation in early trial results ◦https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/ [https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/]  How to reach us: Please donate to: Samaritan’s Purse https://www.samaritanspurse.org/ [https://www.samaritanspurse.org/]  Mark Arnold https://www.linkedin.com/in/markearnoldphd/ [https://www.linkedin.com/in/markearnoldphd/]  Blog - https://bioanalysisandbiomarkers.blogspot.com/ [https://bioanalysisandbiomarkers.blogspot.com/]    Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ [https://www.linkedin.com/in/chadbriscoe/]  Celerion - https://www.celerion.com/ [https://www.celerion.com/]   Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ [https://www.linkedin.com/in/gregoryaustin1/]  ECI - https://eci-rx.com [https://eci-rx.com/] /  Image Credits * AAPS

BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe engage with Dr. Tomas Helikar in an exciting discussion on the future of AI, digital twins, and personalized medicine. From mathematical models and immune system simulations to groundbreaking collaborations with the Department of Defense, this episode uncovers how digital twins have the potential to transform drug discovery and clinical trials. Don’t miss insights on the ethical challenges of data privacy, the promise of animal digital twins, and the latest AI breakthroughs like MIT’s Sparrow algorithm! Chapters 01:00 How the mathematical models work. Normalization and Scaling in Computational Biology 07:55 Focus on the Immune System and Organ Models 09:05 Collaboration with the Department of Defense 11:03 Drug Discovery and Digital Twins 13:43 NEW NEWS! - AI in Drug Discovery: The MIT Sparrow Algorithm 17:51 Future of Digital Twins in Clinical Trials 18:59 Personalized Medicine and Individualized Treatments 23:33 The Potential of Animal Digital Twins 24:59 Building a Research Infrastructure for Digital Twins 26:03 Privacy and Ownership of Digital Twin Data 30:14 Encouraging Publication and Literature Engagement How to reach us: Tomas Helikar  https://www.linkedin.com/in/tomashelikar/ [https://www.linkedin.com/in/tomashelikar/]  X - https://x.com/tomashelikar [https://x.com/tomashelikar]  Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ [https://www.linkedin.com/in/chadbriscoe/]  Celerion - https://www.celerion.com/ [https://www.celerion.com/]   Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ [https://www.linkedin.com/in/gregoryaustin1/]  ECI - https://eci-rx.com [https://eci-rx.com] /  Sound Bites "Publications are the currency in academia." New News Story:  * MIT’s SPARROW Redefines Drug Discovery With Smart Synthesis * https://scitechdaily.com/mits-sparrow-redefines-drug-discovery-with-smart-synthesis/ [https://scitechdaily.com/mits-sparrow-redefines-drug-discovery-with-smart-synthesis/] Image Credits * MIT Molecule, https://news.mit.edu/topic/algorithms?page=2 [https://news.mit.edu/topic/algorithms?page=2]

Dr. Tomas Helikar, a leading researcher in bioinformatics and systems biology, delves into groundbreaking work on developing a personalized immune digital twin, which aims to revolutionize the understanding and treatment of immune-related diseases.  Chapters 00:00 Introduction to BioTalk Unzipped 01:50 Meet Dr. Tomas Helikar 04:34 The Journey into Systems Biology 10:03 Understanding Digital Twins in Immunology 14:19 The Importance of Personalized Medicine 17:20 Digital Twin Research Funding and Its Impact 18:38 The Role of Digital Twins in Disease Management 21:11 Digital Twin Efforts for Organ Transplants 24:05 Computational Challenges in Modeling 26:36 Mathematical Models in Biological Research 28:11 - NEW NEWS! - Twist Joins Absci in AI Antibody Collaboration How to reach us: Tomas Helikar  https://www.linkedin.com/in/tomashelikar/ [https://www.linkedin.com/in/tomashelikar/]  X - https://x.com/tomashelikar [https://x.com/tomashelikar]  Dr. Chad Briscoe https://www.linkedin.com/in/chadbriscoe/ [https://www.linkedin.com/in/chadbriscoe/]  Celerion - https://www.celerion.com/ [https://www.celerion.com/]   Gregory Austin https://www.linkedin.com/in/gregoryaustin1/ [https://www.linkedin.com/in/gregoryaustin1/]  ECI - https://eci-rx.com [https://eci-rx.com] /  Charity Mentioned: https://saintpeterlincoln.com/school [https://saintpeterlincoln.com/school]  FOLLOW ► LinkedIn: https://www.linkedin.com/company/biotalk-unzipped [https://www.linkedin.com/company/biotalk-unzipped] Twitter: https://x.com/BiotalkUnzipped [https://x.com/BiotalkUnzipped] Instagram: https://www.instagram.com/biotalkunzipped/ [https://www.instagram.com/biotalkunzipped/]  Takeaways * Dr. Helikar's research focuses on the immune system's network and disease. * Systems biology integrates computer science and biology for better understanding. * Digital twins can provide personalized models for immune system analysis. * Your digital twin model could tell you how you might respond to a particular disease and if you really need to go to the hospital. * The immune digital twin reflects an individual's unique immune baseline. * Research funding is crucial for advancing innovative medical technologies. * Personalized medicine can improve public health outcomes significantly. * Computational power is essential for processing complex biological data. * Mathematical models are vital for simulating biological processes. * Digital twins can enhance drug discovery and clinical trial efficiency. Sound Bites "The immune system is a network of networks." “Each of our immune system baselines are different.” "We need to build out this multi-scale model." New News Story:  * Supplier-Turned-Partner: Twist Joins Absci in AI Antibody Collaboration * https://www.genengnews.com/topics/drug-discovery/supplier-turned-partner-twist-joins-absci-in-ai-antibody-collaboration/ [https://www.genengnews.com/topics/drug-discovery/supplier-turned-partner-twist-joins-absci-in-ai-antibody-collaboration/] Image Credits * Signal Transduction, www.scientificanimations.com - http://www.scientificanimations.com/wiki-images/ [http://www.scientificanimations.com/wiki-images/] * Computational Model, https://computationstructures.org/notes/models/notes.html [https://computationstructures.org/notes/models/notes.html]  * Holland computer center, https://newsroom.unl.edu/announce/cse/16380/90600 [https://newsroom.unl.edu/announce/cse/16380/90600]  * https://news.unl.edu/article/husker-football-game-day-information-announced-for-2023 [https://news.unl.edu/article/husker-football-game-day-information-announced-for-2023] * https://hcc.unl.edu/office-locations [https://hcc.unl.edu/office-locations]

Dr. Mark Arnold, a distinguished bioanalytical thought leader with an impressive track record in supporting drug development programs. Mark is the Owner and Principal at Bioanalytical Solution Integration, where he provides strategic counsel on complex bioanalytical assays and regulatory compliance. With over 35  years of experience, including leadership roles at BMS and Labcorp, Mark has become a key figure in the biotech and pharma industries. He is also an AAPS Fellow and a founder of the Global Bioanalysis Consortium.  01:05 - Career Reflections and Contributions to Drug Development 05:28 - Understanding the Integration of Drug Development 09:30 - What Would You Change? Embracing Career Risks in Pharma 11:32 - Navigating Career Paths: Small vs. Large Companies 16:09 - NEW NEWS! - Can Electrical Fields Disrupt Cancer? 23:28 - The Role of AI in Drug Development 31:13 - Encouraging Innovation in a Regulated Industry Follow Mark, Chad and Gregory: Please donate to: Samaritan’s Purse https://www.samaritanspurse.org/ [https://www.samaritanspurse.org/]  Mark Arnold - https://www.linkedin.com/in/markearnoldphd/ [https://www.linkedin.com/in/markearnoldphd/]  Blog - https://bioanalysisandbiomarkers.blogspot.com/ [https://bioanalysisandbiomarkers.blogspot.com/]    Dr. Chad Briscoe - https://www.linkedin.com/in/chadbriscoe/ [https://www.linkedin.com/in/chadbriscoe/]  Celerion - https://www.celerion.com/ [https://www.celerion.com/]   Gregory Austin - https://www.linkedin.com/in/gregoryaustin1/ [https://www.linkedin.com/in/gregoryaustin1/]  ECI - https://eci-rx.com [https://eci-rx.com] /  BioTalk Unzipped on LinkedIn - https://www.linkedin.com/company/biotalk-unzipped/ [https://www.linkedin.com/company/biotalk-unzipped/]  New News Story:  * Novocure wins FDA approval for electric field device in lung cancer * https://www.biopharmadive.com/news/novocure-fda-lung-cancer-approval-optune-lua-tumor-treating-field/729997 [https://www.biopharmadive.com/news/novocure-fda-lung-cancer-approval-optune-lua-tumor-treating-field/729997] Two articles on finding 1000’s of dark matter RNA viruses:   * https://www.fiercebiotech.com/research/deep-learning-ai-model-scans-dark-matter-genomic-data-and-finds-70000-never-seen-rna [https://www.fiercebiotech.com/research/deep-learning-ai-model-scans-dark-matter-genomic-data-and-finds-70000-never-seen-rna] * https://www.nature.com/articles/d41586-024-03320-6 [https://www.nature.com/articles/d41586-024-03320-6] Image Credits * Novocure images courtesy of Novocure: www.novocure.com [http://www.novocure.com]